Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
| Website | https://www.remepy.com/ |
| Employees | 89 (56 on RocketReach) |
| Founded | 2022 |
| Industry | Biotechnology Research |
| Keywords | Pharmaceutical Research, Drug Development, New Drug Modalities, Combination Therapies, Advanced Therapeutics, Innovative Drug Delivery, Novel Drug Delivery, Clinical Trials, Therapeutic Solutions, Personalized Medicine, Health Solutions |
| Competitors | Zocdoc, Talkspace, Amwell, Healthgrades, MDLIVE, by Evernorth, SimplePractice, Cerebral, PlushCare, TherapyNotes, LLC, doxy.me - telemedicine for all +29 more (view full list) |
Looking for a particular Remepy employee's phone or email?
Or Shoval is the Co-Founder and Co-CEO of Remepy.
56 people are employed at Remepy.
Remepy is based in New York, New York.